| Title | Influence of CYP3A and CYP2C19 Genetic Polymorphisms on the Pharmacokinetics of Cilostazol in Healthy Subjects. | | Author(s) | Yoo HD, Park SA, Cho HY, Lee YB | | Institution | College of Pharmacy and Institute of Bioequivalence and Bridging Study, Chonnam National University, Gwangju, Korea. | | Source | Clin Pharmacol Ther 2009 Jun 10. | | Abstract | The objective of this study was to investigate the influence of genetic polymorphisms in the CYP3A and CYP2C19 genes on cilostazol pharmacokinetics, with the drug being administered orally as a 50-mg single dose in healthy subjects. CYP2C19 genotypes in individuals with the CYP3A5*3/*3 genotype were associated with statistically significant differences (P < 0.05) in cilostazol pharmacokinetics parameters (apparent oral clearance (CL/F) and terminal half-life (t(1/2))). This indicates that CYP2C19 polymorphisms play an important role in the metabolism of cilostazol only in individuals with the CYP3A5*3/*3 genotype, which has low metabolic activity.Clinical Pharmacology & Therapeutics (2009); advance online publication 10 June 2009. doi:10.1038/clpt.2009.90. | | Language | ENG | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 19516253 |
|
